Efficacy and Safety of Avelumab Plus Axitinib vs Sunitinib by IMDC Risk Groups in Patients With Advanced RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
ESMO Open 2023 Apr 25;8(3)101210, JBAG Haanen, J Larkin, TK Choueiri, L Albiges, BI Rini, MB Atkins, M Schmidinger, K Penkov, E Michelon, J Wang, M Mariani, A di Pietro, RJ MotzerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.